Table 4.
Relative Risk (95% confidence interval) of Less-favorable Invasive Cancer Characteristics for Biennial versus Annual Screeners, by Age, Menopausal Status, and Current Hormone Therapy Use, Adjusted for Race/Ethnicity, First-Degree Family History of Breast Cancer, and Breast Cancer Surveillance Consortium Registry Using Log-Binomial Regression Unless Otherwise Specified
| Tumor Prognostic Characteristic |
||||
|---|---|---|---|---|
| Stage IIB, III, or IV vs. I or IIAa | Tumor size >15 mm vs. <=15 mma | Lymph node positive vs. negative | Less- vs. more-favorable prognostic characteristicsa,b | |
| Age | ||||
| 40-49 y | 1.17 (0.93, 1.46) | 1.10 (0.98, 1.25) | 1.09 (0.92, 1.29) | 1.04 (0.94, 1.14) |
| 50-59 y | 0.98 (0.80, 1.21) | 1.09 (0.97, 1.21) | 1.05 (0.90, 1.22) | 1.03 (0.94, 1.12) |
| 60-69 y | 0.99 (0.79, 1.24) | 1.13 (1.00, 1.27) | 0.93 (0.78, 1.12) | 1.07 (0.97, 1.19) |
| 70-85 y | 0.98 (0.76, 1.27) | 1.13 (0.99, 1.29) | 0.91 (0.74, 1.12) | 1.05 (0.94, 1.18) |
| Menopausal status | ||||
| Premenopausal | 1.28 (1.01, 1.63) | 1.21 (1.07, 1.37) | 1.15 (0.96, 1.38) | 1.11 (1.00, 1.22) |
| Postmenopausal, without HT use | 0.95 (0.79, 1.15) | 1.11 (1.00, 1.22) | 0.89 (0.77, 1.04) | 1.03 (0.95, 1.12) |
| Postmenopausal, with HT use | 1.14 (0.89, 1.47) | 1.13 (0.98, 1.31) | 1.18 (0.98, 1.42) | 1.12 (1.00, 1.25) |
| Estrogen plus progestogen usedc | 1.01 (0.94, 1.08)d | 1.38 (1.04, 1.82) | 0.95 (0.64, 1.41) | 1.16 (0.91, 1.47) |
| Estrogen only usedc | 1.19 (0.78, 1.83) | 1.19 (0.95, 1.50) | 1.26 (0.90, 1.77) | 1.14 (0.94, 1.37) |
Abbreviation: HT, postmenopausal hormone therapy.
Bold, significantly different from one.
Less favorable = stage IIB or higher, size >15 mm, or node positive.
Analysis restricted to women with known hysterectomy status: with uterus assumed to be estrogen plus progestogen; without uterus assumed to be estrogen only.
Relative risk estimated by Poisson regression with robust error variance.